Elemene Promotes Clinical Efficacy of Multiple Kinase Inhibitor Lenvatinib and Programmed Death-1 Inhibitor Tislelizumab Combination in Advanced Hepatocellular Carcinoma

IF 0.4 4区医学 Q4 NUTRITION & DIETETICS Current Topics in Nutraceutical Research Pub Date : 2023-10-09 DOI:10.37290/ctnr2641-452x.21:386-394

Jie Duan, Wei Chen, Changhao Chen, Fangnan Song, Faxi Chen, Fangfang Jiang, Huiwen Xing, Aidong Gu

{"title":"Elemene Promotes Clinical Efficacy of Multiple Kinase Inhibitor Lenvatinib and Programmed Death-1 Inhibitor Tislelizumab Combination in Advanced Hepatocellular Carcinoma","authors":"Jie Duan, Wei Chen, Changhao Chen, Fangnan Song, Faxi Chen, Fangfang Jiang, Huiwen Xing, Aidong Gu","doi":"10.37290/ctnr2641-452x.21:386-394","DOIUrl":null,"url":null,"abstract":"We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P < 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P > 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.","PeriodicalId":10976,"journal":{"name":"Current Topics in Nutraceutical Research","volume":null,"pages":null},"PeriodicalIF":0.4000,"publicationDate":"2023-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Topics in Nutraceutical Research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.37290/ctnr2641-452x.21:386-394","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

We have examined the effect of added elemene on the clinical efficacy of combined treatment of advanced hepatocellular carcinoma with lenvatinib and tislelizumab chemotherapy. Patients with advanced hepatocellular carcinoma (n = 150) were divided into groups of equal size and treated with the multi-kinase inhibitor lenvatinib plus the PD-1 inhibitor tislelizumab alone (control) or along with elemene (treatment), a plant sesquiterpene with antiproliferative effects. The results of the study show a higher objective response rate and local control rate, superior post-treatment liver function, immune function, anti-angiogenesis capacity, and better quality of life, as reflected by higher functional assessment of cancer therapy scores (P < 0.05). Additionally, after treatment, albumin and prealbumin were elevated, and patient-generated subjective global assessment scores declined in both groups after treatment, but no difference was found between the two groups (P > 0.05). To sum up, elemene added to lenvatinib and tislelizumab chemotherapy is effective in treating advanced hepatocellular carcinoma patients and is recommended for clinical use.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

榄香烯促进多激酶抑制剂Lenvatinib和程序性死亡-1抑制剂Tislelizumab联合治疗晚期肝细胞癌的临床疗效

我们研究了添加榄香烯对莱瓦替尼联合替利单抗化疗治疗晚期肝癌临床疗效的影响。晚期肝细胞癌患者(n = 150)被分成大小相等的组，接受多激酶抑制剂lenvatinib加PD-1抑制剂tislelizumab单独治疗(对照组)或与榄香烯(治疗)联合治疗(治疗)，榄香烯是一种具有抗增殖作用的植物倍半萜。研究结果显示，患者客观缓解率和局部控制率较高，治疗后肝功能、免疫功能、抗血管生成能力较好，生活质量较好，癌症治疗评分功能评价较高(P <0.05)。此外，治疗后两组患者的白蛋白和前白蛋白均升高，患者主观总体评估评分均下降，但两组间无差异(P >0.05)。综上所述，lenvatinib和tislelizumab化疗方案中加入榄香烯治疗晚期肝癌患者是有效的，推荐临床使用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Topics in Nutraceutical Research 医学-药学

CiteScore

1.10

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Current Topics in Nutraceutical Research is an international, interdisciplinary broad-based peer reviewed scientific journal for critical evaluation of research on chemistry, biology and therapeutic applications of nutraceuticals and functional foods. The major goal of this journal is to provide peer reviewed unbiased scientific data to the decision makers in the nutraceutical and food industry to help make informed choices about development of new products. To this end, the journal will publish two types of review articles. First, a review of preclinical research data coming largely from animal, cell culture and other experimental models. Such data will provide basis for future product development and/or human research initiatives. Second, a critical evaluation of current human experimental data to help market and deliver the product for medically proven use. This journal will also serve as a forum for nutritionists, internists, neurologists, psychiatrists, and all those interested in preventive medicine. The common denominator of all of the topic to be covered by the journal must include nutraceuticals and/functional food. The following is an example of some specific areas that may be of interest to the journal. i) Role of vitamins, minerals, antioxidants and phytonutrients on cardiovascular health, cancer, diabetes, ocular health, mental health, men’s health, women’s health, infant nutrition, ii) Role of herbals on human health, iii) Dietary supplements and sleep, iv) Components of diet that may have beneficial effect on human health, v) regulation of apoptosis and cell viability, vi) Isolation and characterization of bioactive components from functional foods, vii) Nutritional genomics, and viii) Nutritional proteomics.